ATE349211T1 - Dual bindende acetylcholinesterase inhibitoren zur behandlung von alzheimer - Google Patents

Dual bindende acetylcholinesterase inhibitoren zur behandlung von alzheimer

Info

Publication number
ATE349211T1
ATE349211T1 AT03751019T AT03751019T ATE349211T1 AT E349211 T1 ATE349211 T1 AT E349211T1 AT 03751019 T AT03751019 T AT 03751019T AT 03751019 T AT03751019 T AT 03751019T AT E349211 T1 ATE349211 T1 AT E349211T1
Authority
AT
Austria
Prior art keywords
disease
treatment
alzheimer
acetylcholinesterase inhibitors
dual binding
Prior art date
Application number
AT03751019T
Other languages
English (en)
Inventor
Gil Ana Martinez
Diaz Isabel Dorronsoro
Arrieta Laura Rubio
Gordillo Diana Alonso
Huerta Ana Fuertes
Susana Morales-Alcelay
Monte Millan Maria Del
Palomero Esther Garcia
Egea Paola Usan
Austria Celia De
Padilla Miguel Medina
Original Assignee
Neuropharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropharma Sa filed Critical Neuropharma Sa
Application granted granted Critical
Publication of ATE349211T1 publication Critical patent/ATE349211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03751019T 2002-10-09 2003-10-07 Dual bindende acetylcholinesterase inhibitoren zur behandlung von alzheimer ATE349211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0223494.6A GB0223494D0 (en) 2002-10-09 2002-10-09 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE349211T1 true ATE349211T1 (de) 2007-01-15

Family

ID=9945614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03751019T ATE349211T1 (de) 2002-10-09 2003-10-07 Dual bindende acetylcholinesterase inhibitoren zur behandlung von alzheimer

Country Status (16)

Country Link
US (1) US20060142323A1 (de)
EP (1) EP1558255B1 (de)
JP (1) JP4652054B2 (de)
CN (1) CN100436421C (de)
AT (1) ATE349211T1 (de)
AU (1) AU2003269240B2 (de)
CA (1) CA2501491A1 (de)
DE (1) DE60310753T2 (de)
DK (1) DK1558255T3 (de)
ES (1) ES2279143T3 (de)
GB (1) GB0223494D0 (de)
MX (1) MXPA05003734A (de)
PL (1) PL375018A1 (de)
PT (1) PT1558255E (de)
RU (1) RU2325379C2 (de)
WO (1) WO2004032929A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316094D0 (en) * 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
DE102005009909A1 (de) 2005-03-01 2006-09-07 Heinrich-Heine-Universität Düsseldorf Verbindungen geeignet zur Beseitigung fehlgefalteter Proteine
ES2288406B1 (es) * 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CN102391180B (zh) * 2011-03-07 2014-04-09 华中科技大学 含巯基他克林衍生物及其制备方法和应用
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
WO2012165981A1 (en) 2011-06-03 2012-12-06 Uniwersytet Warszawski Novel hybrid cholinesterase inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2818467A1 (de) * 2013-06-27 2014-12-31 Universitat de Barcelona Multi-Target-Wirkstoffverbindungen zur Behandlung von neurodegenerativen Erkrankungen
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
CN104003987B (zh) * 2014-06-03 2016-03-23 中国药科大学 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂
WO2016146655A1 (en) * 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
PL235351B1 (pl) * 2017-08-09 2020-06-29 Univ Medyczny W Lodzi N-podstawione związki takryny, sposób wytwarzania oraz zastosowanie tych związków
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
RU2675794C1 (ru) * 2017-11-01 2018-12-25 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) Мультифункциональные конъюгаты такрина и его аналогов с производными 1,2,4-тиадиазола, способ их синтеза и применение для лечения нейродегенеративных заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02152967A (ja) * 1988-12-02 1990-06-12 Mitsubishi Kasei Corp ９−アシルアミノ−テトラヒドロアクリジン誘導体及び該誘導体を有効成分とする記憶障害改善剤
US4916135A (en) * 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
JP2720517B2 (ja) * 1989-05-31 1998-03-04 三菱化学株式会社 ９―アシルアミノーテトラヒドロアクリジン誘導体および該誘導体を有効成分とする記憶障害改善剤
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
JPH06184152A (ja) * 1991-11-18 1994-07-05 Sanwa Kagaku Kenkyusho Co Ltd 新規な化合物、その製法及び該化合物を主成分とする脳機能改善剤
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease

Also Published As

Publication number Publication date
CN1703220A (zh) 2005-11-30
PL375018A1 (en) 2005-11-14
EP1558255B1 (de) 2006-12-27
AU2003269240B2 (en) 2010-02-18
ES2279143T3 (es) 2007-08-16
JP2006514922A (ja) 2006-05-18
AU2003269240A1 (en) 2004-05-04
RU2005114353A (ru) 2005-11-10
PT1558255E (pt) 2007-03-30
US20060142323A1 (en) 2006-06-29
MXPA05003734A (es) 2005-09-30
CA2501491A1 (en) 2004-04-22
RU2325379C2 (ru) 2008-05-27
GB0223494D0 (en) 2002-11-13
JP4652054B2 (ja) 2011-03-16
DE60310753D1 (de) 2007-02-08
WO2004032929A3 (en) 2004-07-01
CN100436421C (zh) 2008-11-26
DK1558255T3 (da) 2007-05-07
DE60310753T2 (de) 2007-10-11
WO2004032929A2 (en) 2004-04-22
EP1558255A2 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
ATE349211T1 (de) Dual bindende acetylcholinesterase inhibitoren zur behandlung von alzheimer
ATE455763T1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
MXPA06002727A (es) Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis.
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
ATE274494T1 (de) Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
FR2723091B1 (fr) Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
GB0428232D0 (en) Compounds
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
DE602007012272D1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
DE60130691D1 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
TW200633956A (en) Compounds
DE60020833D1 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
DE602004009099D1 (de) Verwendung von 2-thia-dibenzoäe,hüazulenen zur behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1558255

Country of ref document: EP